Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO Immuno-Oncology 2022 | Advances in utilizing neoadjuvant immunotherapy in melanoma

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses the role of neoadjuvant immunotherapy in melanoma. Findings from the Phase II SWOG S1801 trial (NCT03698019) demonstrated the superiority of neoadjuvant pembrolizumab. Using ctDNA analysis as well as pre- and post-treatment biopsies can guide patients towards better treatment strategies. Multiple clinical trials including the KEYMAKER-U02 (NCT04305054) and MORPHEUS (NCT05116202) will further investigate novel neoadjuvant regimens and treatment markers. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.